Merck also goes for all-comers in adjuvant lung
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
November's CHMP meeting sets up a GSK-Novartis battle
Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer.
Another twist in the TIGIT saga
A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.
